Advertisement

Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies

Published:November 04, 2020DOI:https://doi.org/10.1016/j.ygyno.2020.10.017

      Highlights

      • USC is a distinct type of uterine cancer with poor prognosis, responsible for up to 40% of uterine cancer-related deaths.
      • Molecular features of USC include TP53 mutation, cell cycle changes, ERBB2 amplification, and changes in PI3K signaling.
      • Recent advances in USC therapy include addition of trastuzumab to chemotherapy in ERBB2-amplified cancers.
      • The combination of pembrolizumab and lenvatinib has also demonstrated substantial activity in USC.
      • Novel therapies targeting HER2 and PI3K signaling or the DNA damage response pathway are being developed in USC.

      Abstract

      Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer. Multimodality treatment with surgery, radiotherapy, and chemotherapy is commonly used, given its propensity for extrauterine spread, distant recurrences, and poor prognosis. However, the use of molecularly-based therapy is expanding. Here, we review key molecular features of USC, discuss current management, and assess the landscape of novel therapies and combinations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2020.
        CA Cancer J. Clin. 2020; 70: 7-30https://doi.org/10.3322/caac.21590
        • McGunigal M.
        • Liu J.
        • Kalir T.
        • Chadha M.
        • Gupta V.
        Survival differences among uterine papillary serous, clear cell and grade 3 endometrioid adenocarcinoma endometrial cancers: a national cancer database analysis.
        in: Int. J. Gynecol. Cancer. Lippincott Williams and Wilkins, 2017: 85-92https://doi.org/10.1097/IGC.0000000000000844
        • Kurman R.
        • Carcangiu M.L.
        • Herrington C.S.
        • Young R.H.
        WHO Classification of Tumours of Female Reproductive Organs.
        Lyon IARC Press, 2014
        • Zheng W.
        • Xiang L.
        • Fadare O.
        • Kong B.
        A proposed model for endometrial serous carcinogenesis.
        Am. J. Surg. Pathol. 2011; 35: 1-14https://doi.org/10.1097/PAS.0b013e318202772e
        • Tolcher M.C.
        • Swisher E.M.
        • Medeiros F.
        • Lima J.F.
        • Hilderbrand J.L.
        • Donovan J.L.
        • Garcia R.L.
        • Cliby W.A.
        • Dowdy S.C.
        Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma.
        Int. J. Gynecol. Pathol. 2015; 34: 57-64https://doi.org/10.1097/PGP.0000000000000109
        • Kuhn E.
        • Wu R.C.
        • Guan B.
        • Wu G.
        • Zhang J.
        • Wang Y.
        • Song L.
        • Yuan X.
        • Wei L.
        • Roden R.B.S.
        • Kuo K.T.
        • Nakayama K.
        • Clarke B.
        • Shaw P.
        • Olvera N.
        • Kurman R.J.
        • Levine D.A.
        • Wang T.L.
        • Shih I.M.
        Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
        J. Natl. Cancer Inst. 2012; 104: 1503-1513https://doi.org/10.1093/jnci/djs345
        • Slomovitz B.M.
        • Burke T.W.
        • Eifel P.J.
        • Ramondetta L.M.
        • Silva E.G.
        • Jhingran A.
        • Oh J.C.
        • Atkinson E.N.
        • Broaddus R.R.
        • Gershenson D.M.
        • Lu K.H.
        Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases.
        Gynecol. Oncol. 2003; 91: 463-469https://doi.org/10.1016/j.ygyno.2003.08.018
        • Liang S.X.
        • Pearl M.
        • Liang S.
        • Xiang L.
        • Jia L.
        • Yang B.
        • Fadare O.
        • Schwartz P.E.
        • Chambers S.K.
        • Kong B.
        • Zheng W.
        Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger.
        Int. J. Cancer. 2011; 128: 763-770https://doi.org/10.1002/ijc.25395
        • Shu C.A.
        • Pike M.C.
        • Jotwani A.R.
        • Friebel T.M.
        • Soslow R.A.
        • Levine D.A.
        • Nathanson K.L.
        • Konner J.A.
        • Arnold A.G.
        • Bogomolniy F.
        • Dao F.
        • Olvera N.
        • Bancroft E.K.
        • Goldfrank D.J.
        • Stadler Z.K.
        • Robson M.E.
        • Brown C.L.
        • Leitao M.M.
        • Abu-Rustum N.R.
        • Aghajanian C.A.
        • Blum J.L.
        • Neuhausen S.L.
        • Garber J.E.
        • Daly M.B.
        • Isaacs C.
        • Eeles R.A.
        • Ganz P.A.
        • Barakat R.R.
        • Offit K.
        • Domchek S.M.
        • Rebbeck T.R.
        • Kauff N.D.
        Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA Mutations.
        JAMA Oncol. 2016; 2: 1434-1440https://doi.org/10.1001/jamaoncol.2016.1820
        • Gerber D.
        • Dao F.
        • Olvera N.
        • Piccola N.
        • Levine D.A.
        Frequency of BRCA1 and BRCA2 germline mutations in uterine serous carcinomas and uterine carcinosarcomas.
        J. Clin. Oncol. 2018; 36: e13521https://doi.org/10.1200/JCO.2018.36.15_suppl.e13521
        • Zhao S.
        • Choi M.
        • Overton J.D.
        • Bellone S.
        • Roque D.M.
        • Cocco E.
        • Guzzo F.
        • English D.P.
        • Varughese J.
        • Gasparrini S.
        • Bortolomai I.
        • Buza N.
        • Hui P.
        • Abu-Khalaf M.
        • Ravaggi A.
        • Bignotti E.
        • Bandiera E.
        • Romani C.
        • Todeschini P.
        • Tassi R.
        • Zanotti L.
        • Carrara L.
        • Pecorelli S.
        • Silasi D.A.
        • Ratner E.
        • Azodi M.
        • Schwartz P.E.
        • Rutherford T.J.
        • Stiegler A.L.
        • Mane S.
        • Boggon T.J.
        • Schlessinger J.
        • Lifton R.P.
        • Santin A.D.
        Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
        Proc. Natl. Acad. Sci. U. S. A. 2013; 110: 2916-2921https://doi.org/10.1073/pnas.1222577110
        • Getz G.
        • Gabriel S.B.
        • Cibulskis K.
        • Lander E.
        • Sivachenko A.
        • Sougnez C.
        • Lawrence M.
        • Kandoth C.
        • Dooling D.
        • Fulton R.
        • Fulton L.
        • Kalicki-Veizer J.
        • McLellan M.D.
        • O’Laughlin M.
        • Schmidt H.
        • Wilson R.K.
        • Ye K.
        • Li D.
        • Ally A.
        • Balasundaram M.
        • Birol I.
        • Butterfield Y.S.N.
        • Carlsen R.
        • Carter C.
        • Chu A.
        • Chuah E.
        • Chun H.J.E.
        • Dhalla N.
        • Guin R.
        • Hirst C.
        • Holt R.A.
        • Jones S.J.M.
        • Lee D.
        • Li H.I.
        • Marra M.A.
        • Mayo M.
        • Moore R.A.
        • Mungall A.J.
        • Plettner P.
        • Schein J.E.
        • Sipahimalani P.
        • Tam A.
        • Varhol R.J.
        • Robertson A. Gordon
        • Cherniack A.D.
        • Pashtan I.
        • Saksena G.
        • Onofrio R.C.
        • Schumacher S.E.
        • Tabak B.
        • Carter S.L.
        • Hernandez B.
        • Gentry J.
        • Salvesen H.B.
        • Ardlie K.
        • Winckler W.
        • Beroukhim R.
        • Meyerson M.
        • Hadjipanayis A.
        • Lee S.
        • Mahadeshwar H.S.
        • Park P.
        • Protopopov A.
        • Ren X.
        • Seth S.
        • Song X.
        • Tang J.
        • Xi R.
        • Yang L.
        • Dong Z.
        • Kucherlapati R.
        • Chin L.
        • Zhang J.
        • Auman J. Todd
        • Balu S.
        • Bodenheimer T.
        • Buda E.
        • Hayes D. Neil
        • Hoyle A.P.
        • Jefferys S.R.
        • Jones C.D.
        • Meng S.
        • Mieczkowski P.A.
        • Mose L.E.
        • Parker J.S.
        • Perou C.M.
        • Roach J.
        • Yan S.
        • Simons J.V.
        • Soloway M.G.
        • Tan D.
        • Topal M.D.
        • Waring S.
        • Wu J.
        • Hoadley K.A.
        • Baylin S.B.
        • Bootwalla M.S.
        • Lai P.H.
        • Triche T.J.
        • Van Den Berg D.J.
        • Weisenberger D.J.
        • Laird P.W.
        • Shen H.
        • Cho J.
        • Dicara D.
        • Frazer S.
        • Heiman D.
        • Jing R.
        • Lin P.
        • Mallard W.
        • Stojanov P.
        • Voet D.
        • Zhang H.
        • Zou L.
        • Noble M.
        • Reynolds S.M.
        • Shmulevich I.
        • Aksoy B. Arman
        • Antipin Y.
        • Ciriello G.
        • Dresdner G.
        • Gao J.
        • Gross B.
        • Jacobsen A.
        • Ladanyi M.
        • Reva B.
        • Sander C.
        • Sinha R.
        • Sumer S. Onur
        • Taylor B.S.
        • Cerami E.
        • Weinhold N.
        • Schultz N.
        • Shen R.
        • Benz S.
        • Goldstein T.
        • Haussler D.
        • Ng S.
        • Szeto C.
        • Stuart J.
        • Benz C.C.
        • Yau C.
        • Zhang W.
        • Annala M.
        • Broom B.M.
        • Casasent T.D.
        • Ju Z.
        • Liang H.
        • Liu G.
        • Lu Y.
        • Unruh A.K.
        • Wakefield C.
        • Weinstein J.N.
        • Zhang N.
        • Liu Y.
        • Broaddus R.
        • Akbani R.
        • Mills G.B.
        • Adams C.
        • Barr T.
        • Black A.D.
        • Bowen J.
        • Deardurff J.
        • Frick J.
        • Gastier-Foster J.M.
        • Grossman T.
        • Harper H.A.
        • Hart-Kothari M.
        • Helsel C.
        • Hobensack A.
        • Kuck H.
        • Kneile K.
        • Leraas K.M.
        • Lichtenberg T.M.
        • McAllister C.
        • Pyatt R.E.
        • Ramirez N.C.
        • Tabler T.R.
        • Vanhoose N.
        • White P.
        • Wise L.
        • Zmuda E.
        • Barnabas N.
        • Berry-Green C.
        • Blanc V.
        • Boice L.
        • Button M.
        • Farkas A.
        • Green A.
        • MacKenzie J.
        • Nicholson D.
        • Kalloger S.E.
        • Gilks C. Blake
        • Karlan B.Y.
        • Lester J.
        • Orsulic S.
        • Borowsky M.
        • Cadungog M.
        • Czerwinski C.
        • Huelsenbeck-Dill L.
        • Iacocca M.
        • Petrelli N.
        • Rabeno B.
        • Witkin G.
        • Nemirovich-Danchenko E.
        • Potapova O.
        • Rotin D.
        • Berchuck A.
        • Birrer M.
        • Disaia P.
        • Monovich L.
        • Curley E.
        • Gardner J.
        • Mallery D.
        • Penny R.
        • Dowdy S.C.
        • Winterhoff B.
        • Dao L.
        • Gostout B.
        • Meuter A.
        • Teoman A.
        • Dao F.
        • Olvera N.
        • Bogomolniy F.
        • Garg K.
        • Soslow R.A.
        • Abramov M.
        • Bartlett J.M.S.
        • Kodeeswaran S.
        • Parfitt J.
        • Moiseenko F.
        • Clarke B.A.
        • Goodman M.T.
        • Carney M.E.
        • Matsuno R.K.
        • Fisher J.
        • Huang M.
        • Rathmell W. Kimryn
        • Thorne L.
        • Van Le L.
        • Dhir R.
        • Edwards R.
        • Elishaev E.
        • Zorn K.
        • Goodfellow P.J.
        • Mutch D.
        • Kahn A.B.
        • Bell D.W.
        • Pollock P.M.
        • Wang C.
        • Wheeler D.
        • Shinbrot E.
        • Robertson A. Gordon
        • Ding L.
        • Gilks C. Blake
        • Mardis E.R.
        • Ayala B.
        • Chu A.L.
        • Jensen M.A.
        • Kothiyal P.
        • Pihl T.D.
        • Pontius J.
        • Pot D.A.
        • Snyder E.E.
        • Srinivasan D.
        • Shaw K.R. Mills
        • Sheth M.
        • Davidsen T.
        • Eley G.
        • Ferguson M.L.
        • Yang L.
        • Guyer M.S.
        • Ozenberger B.A.
        • Sofia H.J.
        • Robertson A. Gordon
        • Levine D.A.
        Integrated genomic characterization of endometrial carcinoma.
        Nature. 2013; https://doi.org/10.1038/nature12113
        • Le Gallo M.
        • O’hara A.J.
        • Rudd M.L.
        • Urick M.E.
        • Hansen N.F.
        • O’neil N.J.
        • Price J.C.
        • Zhang S.
        • England B.M.
        • Godwin A.K.
        • Sgroi D.C.
        • Hieter P.
        • Mullikin J.C.
        • Merino M.J.
        • Bell D.W.
        Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program.
        Nat. Genet. 2012; 44https://doi.org/10.1038/ng.2455
        • Schultheis A.M.
        • Martelotto L.G.
        • De Filippo M.R.
        • Piscuglio S.
        • Ng C.K.Y.
        • Hussein Y.R.
        • Reis-Filho J.S.
        • Soslow R.A.
        • Weigelt B.
        TP53 mutational spectrum in endometrioid and serous endometrial cancers.
        Int. J. Gynecol. Pathol. 2016; https://doi.org/10.1097/PGP.0000000000000243
        • Santin A.D.
        • Bellone S.
        • Van Stedum S.
        • Bushen W.
        • De Las Casas L.E.
        • Korourian S.
        • Tian E.
        • Roman J.J.
        • Burnett A.
        • Pecorelli S.
        Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
        Gynecol. Oncol. 2005; 98: 24-30https://doi.org/10.1016/j.ygyno.2005.03.041
        • Togami S.
        • Sasajima Y.
        • Oi T.
        • Ishikawa M.
        • Onda T.
        • Ikeda S.I.
        • Kato T.
        • Tsuda H.
        • Kasamatsu T.
        Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma.
        Cancer Sci. 2012; 103: 926-932https://doi.org/10.1111/j.1349-7006.2012.02240.x
        • Carvajal-Hausdorf D.E.
        • Schalper K.A.
        • Bai Y.
        • Black J.
        • Santin A.D.
        • Rimm D.L.
        Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
        Gynecol. Oncol. 2017; 145: 154-158https://doi.org/10.1016/j.ygyno.2017.02.002
        • Buza N.
        • English D.P.
        • Santin A.D.
        • Hui P.
        Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.
        Mod. Pathol. 2013; 26: 1605-1612https://doi.org/10.1038/modpathol.2013.113
        • Erickson B.K.
        • Najjar O.
        • Damast S.
        • Blakaj A.
        • Tymon-Rosario J.
        • Shahi M.
        • Santin A.
        • Klein M.
        • Dolan M.
        • Cimino-Mathews A.
        • Buza N.
        • Ferriss J.S.
        • Stone R.L.
        • Khalifa M.
        • Fader A.N.
        Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study.
        Gynecol. Oncol. 2020; 159 (Epub 2020 Jul 21. PMID: 32709539; PMCID: PMC7541557): 17-22https://doi.org/10.1016/j.ygyno.2020.07.016
        • Jones N.L.
        • Xiu J.
        • Chatterjee-Paer S.
        • Buckley de Meritens A.
        • Burke W.M.
        • Tergas A.I.
        • Wright J.D.
        • Hou J.Y.
        Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas.
        Int. J. Cancer. 2017; 140: 1396-1404https://doi.org/10.1002/ijc.30537
        • Mahdi H.
        • Xiu J.
        • Reddy S.K.
        • Debernardo R.
        Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
        J. Surg. Oncol. 2015; 112: 188-194https://doi.org/10.1002/jso.23993
        • Cuevas D.
        • Valls J.
        • Gatius S.
        • Roman-Canal B.
        • Estaran E.
        • Dorca E.
        • Santacana M.
        • Vaquero M.
        • Eritja N.
        • Velasco A.
        • Matias-Guiu X.
        Targeted Sequencing With a Customized Panel to Assess Histological Typing in Endometrial Carcinoma.
        2020https://doi.org/10.1007/s00428-018-02516-2 (n.d.)
        • Frimer M.
        • Levano K.S.
        • Rodriguez-Gabin A.
        • Wang Y.
        • Goldberg G.L.
        • Horwitz S.B.
        • Hou J.Y.
        Germline mutations of the DNA repair pathways in uterine serous carcinoma.
        Gynecol. Oncol. 2016; 141: 101-107https://doi.org/10.1016/j.ygyno.2015.12.034
        • Ashley C.W.
        • Paula A.D.C.
        • Kumar R.
        • Mandelker D.
        • Pei X.
        • Riaz N.
        • Reis-Filho J.
        • Weigelt B.
        Homologous recombination DNA repair defects in copy-number high serous-like endometrial cancers.
        Gynecol. Oncol. 2019; : 32https://doi.org/10.1016/j.ygyno.2019.04.077
        • Pennington K.P.
        • Walsh T.
        • Lee M.
        • Pennil C.
        • Novetsky A.P.
        • Agnew K.J.
        • Thornton A.
        • Garcia R.
        • Mutch D.
        • King M.C.
        • Goodfellow P.
        • Swisher E.M.
        BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
        Cancer. 2013; 119: 332-338https://doi.org/10.1002/cncr.27720
        • Cocco E.
        • Lopez S.
        • Black J.
        • Bellone S.
        • Bonazzoli E.
        • Predolini F.
        • Ferrari F.
        • Schwab C.L.
        • Menderes G.
        • Zammataro L.
        • Buza N.
        • Hui P.
        • Wong S.
        • Zhao S.
        • Bai Y.
        • Rimm D.L.
        • Ratner E.
        • Litkouhi B.
        • Silasi D.-A.
        • Azodi M.
        • Schwartz P.E.
        • Santin A.D.
        Dual CCNE1/PIK3CA Targeting Is Synergistic in CCNE1-Amplified/PIK3CA-mutated Uterine Serous Carcinomas In Vitro and In Vivo.
        2016https://doi.org/10.1038/bjc.2016.198
        • Boruta D.M.
        • Gehrig P.A.
        • Fader A.N.
        • Olawaiye A.B.
        Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review.
        Gynecol. Oncol. 2009; 115: 142-153https://doi.org/10.1016/j.ygyno.2009.06.011
        • Skaznik-Wikiel M.E.
        • Ueda S.M.
        • Frasure H.E.
        • Rose P.G.
        • Fleury A.
        • Grumbine F.C.
        • Fader A.N.
        Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype?.
        Acta Cytol. 2011; 55: 255-260https://doi.org/10.1159/000324052
        • Huang G.S.
        • Gebb J.S.
        • Einstein M.H.
        • Shahabi S.
        • Novetsky A.P.
        • Goldberg G.L.
        Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors.
        Am. J. Obstet. Gynecol. 2007; 196: 243.e1-243.e5https://doi.org/10.1016/j.ajog.2006.09.035
        • Committee Opinion No A.C.O.G.
        440: the role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding.
        Obstet. Gynecol. 2009; 114: 409-411https://doi.org/10.1097/AOG.0b013e3181b48feb
        • Wang J.
        • Wieslander C.
        • Hansen G.
        • Cass I.
        • Vasilev S.
        • Holschneider C.H.
        Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers.
        Gynecol. Oncol. 2006; 101: 120-125https://doi.org/10.1016/j.ygyno.2005.09.042
        • Lin M.Y.
        • Dobrotwir A.
        • McNally O.
        • Abu-Rustum N.R.
        • Narayan K.
        Role of imaging in the routine management of endometrial cancer.
        Int. J. Gynecol. Obstet. 2018; 143: 109-117https://doi.org/10.1002/ijgo.12618
        • Schmidt M.
        • Segev Y.
        • Sadeh R.
        • Suzan E.
        • Feferkorn I.
        • Kaldawy A.
        • Kligun G.
        • Lavie O.
        Cancer antigen 125 levels are significantly associated with prognostic parameters in uterine papillary serous carcinoma.
        Int. J. Gynecol. Cancer. 2018; 28: 1311-1317https://doi.org/10.1097/IGC.0000000000001300
        • Moore K.N.
        • Fader A. Nickles
        Uterine papillary serous carcinoma.
        Clin. Obstet. Gynecol. 2011; 54: 278-291https://doi.org/10.1097/GRF.0b013e318218c755
        • Boruta D.M.
        • Gehrig P.A.
        • Groben P.A.
        • Bae-Jump V.
        • Boggess J.F.
        • Fowler W.C.
        • Van Le L.
        Uterine serous and grade 3 endometrioid carcinomas.
        Cancer. 2004; 101: 2214-2221https://doi.org/10.1002/cncr.20645
        • Mhawech-Fauceglia P.
        • Herrmann R.F.
        • Kesterson J.
        • Izevbaye I.
        • Lele S.
        • Odunsi K.
        Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium.
        Eur. J. Surg. Oncol. 2010; 36: 1195-1201https://doi.org/10.1016/j.ejso.2010.09.010
        • Fader A.N.
        • Java J.
        • Tenney M.
        • Ricci S.
        • Gunderson C.C.
        • Temkin S.M.
        • Spirtos N.
        • Kushnir C.L.
        • Pearl M.L.
        • Zivanovic O.
        • Tewari K.S.
        • O’Malley D.
        • Hartenbach E.M.
        • Hamilton C.A.
        • Gould N.S.
        • Mannel R.S.
        • Rodgers W.
        • Walker J.L.
        Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: an NRG Oncology/Gynecologic Oncology Group ancillary analysis.
        Gynecol. Oncol. 2016; 143: 460-465https://doi.org/10.1016/j.ygyno.2016.10.016
        • Fader A.N.
        • Seamon L.G.
        • Escobar P.F.
        • Frasure H.E.
        • Havrilesky L.A.
        • Zanotti K.M.
        • Secord A.A.
        • Boggess J.F.
        • Cohn D.E.
        • Fowler J.M.
        • Skafianos G.
        • Rossi E.
        • Gehrig P.A.
        Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers.
        Gynecol. Oncol. 2012; 126: 180-185https://doi.org/10.1016/j.ygyno.2012.04.028
        • Gehrig P.A.
        • Van Le L.
        • Fowler W.C.
        The role of omentectomy during the surgical staging of uterine serous carcinoma.
        Int. J. Gynecol. Cancer. 2003; 13: 212-215https://doi.org/10.1136/ijgc-00009577-200303000-00019
        • Todo Y.
        • Kato H.
        • Kaneuchi M.
        • Watari H.
        • Takeda M.
        • Sakuragi N.
        Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis.
        Lancet. 2010; 375: 1165-1172https://doi.org/10.1016/S0140-6736(09)62002-X
        • Basaran D.
        • Bruce S.
        • Aviki E.M.
        • Mueller J.J.
        • Broach V.A.
        • Cadoo K.
        • Soslow R.A.
        • Alektiar K.M.
        • Abu-Rustum N.R.
        • Leitao M.M.
        Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma.
        Gynecol. Oncol. 2020; 156: 70-76https://doi.org/10.1016/j.ygyno.2019.10.005
        • Cusimano M.C.
        • Vicus D.
        • Pulman K.
        • Bernardini M.Q.
        • Laframboise S.
        • May T.
        • Bouchard-Fortier G.
        • Hogen L.
        • Gien L.T.
        • Covens A.L.
        • Kupets R.
        • Clarke B.A.
        • Cesari M.
        • Rouzbahman M.
        • Mirkovic J.
        • Turashvili G.
        • Maganti M.
        • Zia A.
        • Ene G.E.V.
        Sentinel lymph node biopsy versus lymphadenectomy for high-grade endometrial cancer staging (SENTOR trial): a prospective multicenter cohort study.
        in: Soc. Gynecol. Oncol. Annu. Meet. 2020
        • Fader A.N.
        • Drake R.D.
        • O’Malley D.M.
        • Gibbons H.E.
        • Huh W.K.
        • Havrilesky L.J.
        • Gehrig P.A.
        • Tuller E.
        • Axtell A.E.
        • Zanotti K.M.
        Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.
        Cancer. 2009; 115: 2119-2127https://doi.org/10.1002/cncr.24247
        • Fader A.N.
        • Starks D.
        • Gehrig P.A.
        • Secord A.A.
        • Frasure H.E.
        • O’Malley D.M.
        • Tuller E.R.
        • Rose P.G.
        • Havrilesky L.J.
        • Moore K.N.
        • Huh W.K.
        • Axtell A.E.
        • Kelley J.L.
        • Zanotti K.M.
        An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
        Gynecol. Oncol. 2009; 115: 244-248https://doi.org/10.1016/j.ygyno.2009.07.030
        • Moller K.A.
        • Gehrig P.A.
        • Van Le L.
        • Secord A.A.
        • Schorge J.
        The role of optimal debulking in advanced stage serous carcinoma of the uterus.
        Gynecol. Oncol. 2004; 94: 170-174https://doi.org/10.1016/j.ygyno.2004.03.040
        • Thomas M.
        • Mariani A.
        • Cliby W.
        • Keeney G.
        • Podratz K.
        • Dowdy S.
        Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
        Gynecol. Oncol. 2007; 107: 190-193https://doi.org/10.1016/j.ygyno.2007.05.039
        • Mahdi H.
        • Rose P.G.
        • Elshaikh M.A.
        • Munkarah A.
        • Isrow D.
        • Singh S.
        • Waggoner S.
        • Ali-Fehmi R.
        • Morris R.T.
        • Harding J.
        • Debenardo R.
        Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage i non-invasive uterine papillary serous carcinoma. A multi-institutional study.
        Gynecol. Oncol. 2015; 136: 529-533https://doi.org/10.1016/j.ygyno.2014.12.034
        • Mahdi H.
        • Elshaikh M.A.
        • Debenardo R.
        • Munkarah A.
        • Isrow D.
        • Singh S.
        • Waggoner S.
        • Ali-Fehmi R.
        • Morris R.T.
        • Harding J.
        • Moslemi-Kebria M.
        Impact of Adjuvant Chemotherapy and Pelvic Radiation on Pattern of Recurrence and Outcome in Stage I Non-invasive Uterine Papillary Serous Carcinoma. A Multi-institution Study.
        2015https://doi.org/10.1016/j.ygyno.2015.01.544
        • Jenkins Vogel T.
        • Knickerbocker A.
        • Shah C.A.
        • Schiff M.A.
        • Isacson C.
        • Garcia R.L.
        • Goff B.A.
        An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
        J. Gynecol. Oncol. 2015; 26: 25-31https://doi.org/10.3802/jgo.2015.26.1.25
        • Cham S.
        • Huang Y.
        • Tergas A.I.
        • Hou J.Y.
        • Burke W.M.
        • Deutsch I.
        • Ananth C.V.
        • Neugut A.I.
        • Hershman D.L.
        • Wright J.D.
        Utility of radiation therapy for early-stage uterine papillary serous carcinoma.
        Gynecol. Oncol. 2017; 145: 269-276https://doi.org/10.1016/j.ygyno.2017.03.003
        • Fader A.N.
        • Nagel C.
        • Axtell A.E.
        • Zanotti K.M.
        • Kelley J.L.
        • Moore K.N.
        • Secord A.A.
        • Walsh C.S.
        • Huh W.K.
        • Gehrig P.A.
        • Gibbons H.
        • Rose P.G.
        • Havrilesky L.J.
        • Tuller E.
        • Drake R.D.
        • Bottsford-Miller J.
        • O’Malley D.M.
        Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
        Gynecol. Oncol. 2009; 112: 558-562https://doi.org/10.1016/j.ygyno.2008.11.016
        • Kelly M.G.
        • O’malley D.M.
        • Hui P.
        • Mcalpine J.
        • Yu H.
        • Rutherford T.J.
        • Azodi M.
        • Schwartz P.E.
        Improved Survival in Surgical Stage I Patients With Uterine Papillary Serous Carcinoma (UPSC) Treated With Adjuvant Platinum-based Chemotherapy.
        2005https://doi.org/10.1016/j.ygyno.2005.06.012
        • Fader A.N.
        • Boruta D.
        • Olawaiye A.B.
        • Gehrig P.A.
        Uterine papillary serous carcinoma: epidemiology, pathogenesis and management.
        Curr. Opin. Obstet. Gynecol. 2010; 22: 21-29https://doi.org/10.1097/GCO.0b013e328334d8a3
        • McMillian N. Nicole
        • Scavone M. Jillian
        • Fisher C.M.
        • Frederick P.
        • Gaffney D.K.
        • George S.
        • Han E.
        • Huh W.K.
        • Lurain J.R.
        • Lurie H. Robert
        • Mariani A.
        • Mutch D.
        • Nagel C.
        • Yashar C.M.
        • Chair V.
        • Bean S.
        • Bradley K.
        • Campos S.M.
        • Chon H. Sook
        • Chu C.
        • Cohn D.
        • Crispens M. Ann
        • Damast S.
        • Dorigo O.
        • Eifel P.J.
        • Nekhlyudov L.
        • Fader A. Nickles
        • Remmenga S.W.
        • Fred
        • P.R. Buffett Cancer Center Kevin Reynolds
        • Tillmanns R. Sisodia T.
        • St Jude
        • Ueda S.
        • Urban R.
        NCCN Guidelines Version 4.2019 Uterine Neoplasms.
        (accessed November 13, 2019)
        • Hui P.
        • Kelly M.
        • O’Malley D.M.
        • Tavassoli F.
        • Schwartz P.E.
        Minimal uterine serous carcinoma: a clinicopathological study of 40 cases.
        Mod. Pathol. 2005; 18: 75-82https://doi.org/10.1038/modpathol.3800271
        • Semaan A.
        • Mert I.
        • Munkarah A.R.
        • Bandyopadhyay S.
        • Mahdi H.S.
        • Winer I.S.
        • Nucci M.R.
        • Hussein Y.
        • Quershi F.
        • Hayek K.
        • Tabassum F.
        • Alosh B.
        • Schultz D.S.
        • Cote M.L.
        • Van De Vijver K.K.
        • Morris R.T.
        • Oliva E.
        • Ali-Fehmi R.
        Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study.
        Int. J. Gynecol. Pathol. 2013; 32: 181-187https://doi.org/10.1097/PGP.0b013e318273fc55
        • Farrell R.
        • Scurry J.
        • Otton G.
        • Hacker N.F.
        Clinicopathologic Review of Malignant Polyps in Stage 1A Carcinoma of the Endometrium.
        2005https://doi.org/10.1016/j.ygyno.2005.03.044
        • Chang-Halpenny C.N.
        • Natarajan S.
        • Hwang-Graziano J.
        Early Stage Papillary Serous or Clear Cell Carcinoma Confined to or Involving an Endometrial Polyp: Outcomes With and Without Adjuvant Therapy.
        2013https://doi.org/10.1016/j.ygyno.2013.10.010
        • Viswanathan A.N.
        • Macklin E.A.
        • Berkowitz R.
        • Matulonis U.
        The Importance of Chemotherapy and Radiation in Uterine Papillary Serous Carcinoma.
        2011https://doi.org/10.1016/j.ygyno.2011.09.005
        • Tortorella L.
        • Langstraat C.L.
        • Weaver A.L.
        • McGree M.E.
        • Bakkum-Gamez J.N.
        • Dowdy S.C.
        • Cliby W.A.
        • Keeney G.L.
        • Sherman M.E.
        • Weroha S.J.
        • Mariani A.
        • Podratz K.C.
        Uterine serous carcinoma: reassessing effectiveness of platinum-based adjuvant therapy.
        Gynecol. Oncol. 2018; 149: 291-296https://doi.org/10.1016/j.ygyno.2018.02.022
        • Hogberg T.
        • Signorelli M.
        • De Oliveira C.F.
        • Fossati R.
        • Lissoni A.A.
        • Sorbe B.
        • Andersson H.
        • Grenman S.
        • Lundgren C.
        • Rosenberg P.
        • Boman K.
        • Tholander B.
        • Scambia G.
        • Reed N.
        • Cormio G.
        • Tognon G.
        • Clarke J.
        • Sawicki T.
        • Zola P.
        • Kristensen G.
        Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies.
        Eur. J. Cancer. 2010; 46: 2422-2431https://doi.org/10.1016/j.ejca.2010.06.002
        • Randall M.E.
        • Filiaci V.
        • Scott D.
        • Von Gruenigen V.
        • Huang H.
        • Yashar C.M.
        • Robert S. Mannel
        • Kim J.-W.
        • Salani R.
        • Disilvestro P.A.
        • Burke J.J.
        • Rutherford T.
        • Nick M. Spirtos
        • Terada Keith
        • Penny R. Anderson
        • Brewster W.R.
        • Small W.
        • Aghajanian C.A.
        • Miller D.S.
        Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/ carboplatin in high-intermediate and high-risk early-stage endometrial cancer.
        J. Clin. Oncol. 2019; 37: 1810-1818https://doi.org/10.1200/JCO.18
        • Randall M.E.
        • Filiaci V.L.
        • Muss H.
        • Spirtos N.M.
        • Mannel R.S.
        • Fowler J.
        • Thigpen J.T.
        • Benda J.A.
        Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study.
        J. Clin. Oncol. 2006; 24: 36-44https://doi.org/10.1200/JCO.2004.00.7617
        • de Boer S.M.
        • Powell M.E.
        • Mileshkin L.
        • Katsaros D.
        • Bessette P.
        • Haie-Meder C.
        • Ottevanger P.B.
        • Ledermann J.A.
        • Khaw P.
        • Colombo A.
        • Fyles A.
        • Baron M.H.
        • Jürgenliemk-Schulz I.M.
        • Kitchener H.C.
        • Nijman H.W.
        • Wilson G.
        • Brooks S.
        • Carinelli S.
        • Provencher D.
        • Hanzen C.
        • Lutgens L.C.H.W.
        • Smit V.T.H.B.M.
        • Singh N.
        • Do V.
        • D’Amico R.
        • Nout R.A.
        • Feeney A.
        • Verhoeven-Adema K.W.
        • Putter H.
        • Creutzberg C.L.
        • McCormack M.
        • Whitmarsh K.
        • Allerton R.
        • Gregory D.
        • Symonds P.
        • Hoskin P.J.
        • Adusumalli M.
        • Anand A.
        • Wade R.
        • Stewart A.
        • Taylor W.
        • Kruitwagen R.F.P.M.
        • Hollema H.
        • Pras E.
        • Snyers A.
        • Stalpers L.
        • Jobsen J.J.
        • Slot A.
        • Mens J.W.M.
        • Stam T.C.
        • Van Triest B.
        • Van der Steen-Banasik E.M.
        • De Winter K.A.J.
        • Quinn M.A.
        • Kolodziej I.
        • Pyman J.
        • Johnson C.
        • Capp A.
        • Fossati R.
        • Gribaudo S.
        • Lissoni A.A.
        • Ferrero A.
        • Artioli G.
        • Davidson C.
        • McLachlin C.M.
        • Ghatage P.
        • Rittenberg P.V.C.
        • Souhami L.
        • Thomas G.
        • Duvillard P.
        • Berton-Rigaud D.
        • Tubiana-Mathieu N.
        Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
        Lancet Oncol. 2018; 19: 295-309https://doi.org/10.1016/S1470-2045(18)30079-2
        • de Boer S.M.
        • Powell M.E.
        • Mileshkin L.
        • Katsaros D.
        • Bessette P.
        • Haie-Meder C.
        • Ottevanger P.B.
        • Ledermann J.A.
        • Khaw P.
        • D’Amico R.
        • Fyles A.
        • Baron M.-H.
        • Jürgenliemk-Schulz I.M.
        • Kitchener H.C.
        • Nijman H.W.
        • Wilson G.
        • Brooks S.
        • Gribaudo S.
        • Provencher D.
        • Hanzen C.
        • Kruitwagen R.F.
        • Smit V.T.H.B.M.
        • Singh N.
        • Do V.
        • Lissoni A.
        • Nout R.A.
        • Feeney A.
        • Verhoeven-Adema K.W.
        • Putter H.
        • Creutzberg C.L.
        • McCormack M.
        • Whitmarsh K.
        • Allerton R.
        • Gregory D.
        • Symonds P.
        • Hoskin P.
        • Adusumalli M.
        • Anand A.
        • Wade R.
        • Stewart A.
        • Taylor W.
        • Lutgens L.
        • Hollema H.
        • Pras E.
        • Snyers A.
        • Westerveld G.
        • Jobsen J.
        • Slot A.
        • Mens J.
        • Stam T.
        • Van Triest B.
        • Van der Steen-Banasik E.
        • De Winter K.
        • Quinn M.
        • Kolodziej I.
        • Pyman J.
        • Johnson C.
        • Capp A.
        • Fossati R.
        • Colombo A.
        • Carinelli S.
        • Ferrero A.
        • Artioli G.
        • Davidson C.
        • McLachlin C.
        • Ghatage P.
        • Rittenberg P.
        • Souhami L.
        • Thomas G.
        • Duvillard P.
        • Berton-Rigaud D.
        • Tubiana-Mathieu N.
        Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
        Lancet Oncol. 2019; 20: 1273-1285https://doi.org/10.1016/s1470-2045(19)30395-x
        • Matei D.
        • Filiaci V.
        • Randall M.E.
        • Mutch D.
        • Steinhoff M.M.
        • DiSilvestro P.A.
        • Moxley K.M.
        • Kim Y.M.
        • Powell M.A.
        • O’Malley D.M.
        • Spirtos N.M.
        • Small W.
        • Tewari K.S.
        • Richards W.E.
        • Nakayama J.
        • Matulonis U.A.
        • Huang H.Q.
        • Miller D.S.
        Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer.
        N. Engl. J. Med. 2019; 380: 2317-2326https://doi.org/10.1056/NEJMoa1813181
        • Lester-Coll N.H.
        • Park H.S.
        • Rutter C.E.
        • Corso C.D.
        • Young M.R.
        • Ratner E.S.
        • Litkouhi B.
        • Decker R.H.
        • Yu J.B.
        • Damast S.
        Who Benefits from Chemoradiation in Stage III-IVA Endometrial Cancer? An analysis of the National Cancer Data Base.
        2016https://doi.org/10.1016/j.ygyno.2016.04.544
        • Xiang M.
        • English D.P.
        • Kidd E.A.
        Defining the Survival Benefit of Adjuvant Pelvic Radiotherapy and Chemotherapy Versus Chemotherapy Alone in Stages III-IVA Endometrial Carcinoma.
        2019https://doi.org/10.1016/j.ygyno.2019.06.020
        • Mahdi H.
        • Nutter B.
        • Abdul-Karim F.
        • Amarnath S.
        • Rose P.G.
        The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone.
        J. Gynecol. Oncol. 2016; 27https://doi.org/10.3802/jgo.2016.27.e19
        • Menderes G.
        • Bonazzoli E.
        • Bellone S.
        • Altwerger G.
        • Black J.D.
        • Dugan K.
        • Pettinella F.
        • Masserdotti A.
        • Riccio F.
        • Bianchi A.
        • Zammataro L.
        • de Haydu C.
        • Buza N.
        • Hui P.
        • Wong S.
        • Huang G.S.
        • Litkouhi B.
        • Ratner E.
        • Silasi D.A.
        • Azodi M.
        • Schwartz P.E.
        • Santin A.D.
        Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
        Gynecol. Oncol. 2017; 147: 145-152https://doi.org/10.1016/j.ygyno.2017.07.009
        • Black J.
        • Menderes G.
        • Bellone S.
        • Schwab C.L.
        • Bonazzoli E.
        • Ferrari F.
        • Predolini F.
        • De Haydu C.
        • Cocco E.
        • Buza N.
        • Hui P.
        • Wong S.
        • Lopez S.
        • Ratner E.
        • Silasi D.-A.
        • Azodi M.
        • Litkouhi B.
        • Schwartz P.E.
        • Goedings P.
        • Beusker P.H.
        • Van Der Lee M.M.C.
        • Timmers C.M.
        • Dokter W.H.A.
        • Santin A.D.
        SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine serous carcinoma with HER2/Neu expression.
        Mol. Cancer Ther. 2016; 15https://doi.org/10.1158/1535-7163.MCT-16-0163
        • Lopez S.
        • Cocco E.
        • Black J.
        • Bellone S.
        • Bonazzoli E.
        • Predolini F.
        • Ferrari F.
        • Schwab C.L.
        • English D.P.
        • Ratner E.
        • Silasi D.A.
        • Azodi M.
        • Schwartz P.E.
        • Terranova C.
        • Angioli R.
        • Santin A.D.
        Dual HER2/PIK3CA targeting overcomes single-agent acquired resistance in HER2-amplified uterine serous carcinoma cell lines in vitro and in vivo.
        Mol. Cancer Ther. 2015; 14: 2519-2526https://doi.org/10.1158/1535-7163.MCT-15-0383
        • Schwab C.L.
        • Bellone S.
        • English D.P.
        • Roque D.M.
        • Lopez S.
        • Cocco E.
        • Nicoletti R.
        • Bortolomai I.
        • Bonazzoli E.
        • Ratner E.
        • Silasi D.A.
        • Azodi M.
        • Schwartz P.E.
        • Rutherford T.J.
        • Santin A.D.
        Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
        Br. J. Cancer. 2014; 111: 1750-1756https://doi.org/10.1038/bjc.2014.519
        • Fleming G.F.
        • Sill M.W.
        • Darcy K.M.
        • McMeekin D.S.
        • Thigpen J.T.
        • Adler L.M.
        • Berek J.S.
        • Chapman J.A.
        • DiSilvestro P.A.
        • Horowitz I.R.
        • Fiorica J.V.
        Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study.
        Gynecol. Oncol. 2010; 116: 15-20https://doi.org/10.1016/j.ygyno.2009.09.025
        • Pelligra S.
        • Buza N.
        • Hui P.
        • Bellone S.
        • Zeybek B.
        • Ratner E.
        • Schwartz P.E.
        • Scambia G.
        • Santin A.D
        Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma.
        Gynecol Oncol Rep. 2020; 32 (PMID: 32140533; PMCID: PMC7049633): 100554https://doi.org/10.1016/j.gore.2020.100554
        • Menderes G.
        • Lopez S.
        • Han C.
        • Altwerger G.
        • Gysler S.
        • Varughese J.
        • Schwartz P.E.
        • Santin A.D.
        Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it.
        Discov. Med. 2018; 26 (accessed November 10, 2019): 39-50
        • Fader A.N.
        • Roque D.M.
        • Siegel E.
        • Buza N.
        • Hui P.
        • Abdelghany O.
        • Chambers S.K.
        • Secord A. Alvarez
        • Havrilesky L.
        • Backes F.
        • Nevadunsky N.
        • Edraki B.
        • Pikaart D.
        • Lowery W.
        • ElSahwi K.S.
        • Celano P.
        • Bellone S.
        • Azodi M.
        • Litkouhi B.
        • Ratner E.
        • Silasi D.-A.
        • Schwartz P.E.
        • Santin A.D.
        Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu.
        J Clin Oncol. 2018; 36 (doi:10.1200/JCO): 2044-2051
        • Fader A.N.
        • Roque D.M.
        • Siegel E.
        • Buza N.
        • Hui P.
        • Abdelghany O.
        • Chambers S.
        • Secord A.A.
        • Havrilesky L.
        • Malley D.M.
        • Backes F.J.
        • Nevadunsky N.
        • Edraki B.
        • Pikaart D.
        • Lowery W.
        • ElSahwi K.
        • Celano P.
        • Bellone S.
        • Azodi M.
        • Litkouhi B.
        • Ratner E.
        • Silasi D.-A.
        • Schwartz P.E.
        • Santin A.D.
        Randomized phase II trial of carboplatin–paclitaxel compared with carboplatin–paclitaxel–trastuzumab in advanced (Stage III–IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis.
        Clin. Cancer Res. 2020; https://doi.org/10.1158/1078-0432.CCR-20-0953
        • Ott P.A.
        • Bang Y.-J.
        • Berton-Rigaud D.
        • Elez E.
        • Pishvaian M.J.
        • Rugo H.S.
        • Puzanov I.
        • Mehnert J.M.
        • Aung K.L.
        • Lopez J.
        • Carrigan M.
        • Saraf S.
        • Chen M.
        • Soria J.-C.
        Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
        2017https://doi.org/10.1200/JCO
        • Konstantinopoulos P.A.
        • Luo W.
        • Liu J.F.
        • Doga C. Gulhan
        • Krasner C.
        • Ishizuka J.J.
        • Gockley A.A.
        • Buss M.
        • Whitfield B. Growdon
        • Crowe Heather
        • Campos S.
        • Lindeman N.I.
        • Hill S.
        • Stover E.
        • Schumer S.
        • Wright A.A.
        • Curtis J.
        • Quinn R.
        • Whalen C.
        • Gray K.P.
        • Penson R.T.
        • Cannistra S.A.
        • Gini
        • Fleming F.
        • Matulonis U.A.
        Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer.
        J. Clin. Oncol. 2019; 37: 2786-2794https://doi.org/10.1200/JCO.19
        • Oaknin A.
        • Duska L.R.
        • Sullivan R.J.
        • Pothuri B.
        • Ellard S.L.
        • Leath C.A.
        • Moreno V.
        • Kristeleit R.S.
        • Guo W.
        • Danaee H.
        • Im E.
        • Gilbert L.
        Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer.
        Gynecol. Oncol. 2019; 154: 17https://doi.org/10.1016/j.ygyno.2019.04.044
        • Makker V.
        • Rasco D.
        • Vogelzang N.J.
        • Brose M.S.
        • Cohn A.L.
        • Mier J.
        • Di Simone C.
        • Hyman D.M.
        • Stepan D.E.
        • Dutcus C.E.
        • Schmidt E.V.
        • Guo M.
        • Sachdev P.
        • Shumaker R.
        • Aghajanian C.
        • Taylor M.
        Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
        Lancet Oncol. 2019; https://doi.org/10.1016/S1470-2045(19)30020-8
        • Yang X.
        • Leslie G.
        • Doroszuk A.
        • Schneider S.
        • Allen J.
        • Decker B.
        • Dunning A.M.
        • Redman J.
        • Scarth J.
        • Plaskocinska I.
        • Luccarini C.
        • Shah M.
        • Pooley K.
        • Dorling L.
        • Lee A.
        • Adank M.A.
        • Adlard J.
        • AittomäkiAittom K.
        • Andrulis I.L.
        • Ang P.
        • Barwell J.
        • Bernstein J.L.
        • Bobolis K.
        • Borg A.
        • Blomqvist C.
        • Claes K.B.
        • Concannon P.
        • Cuggia A.
        • Culver J.O.
        • Damiola F.
        • de Pauw A.
        • Diez O.
        • Dolinsky J.S.
        • Domchek S.M.
        • Engel C.
        • Evans D. Gareth
        • Fostira F.
        • Garber J.
        • Golmard L.
        • Goode E.L.
        • Gruber S.B.
        • Hahnen E.
        • Hake C.
        • Heikkinen T.
        • Hurley J.E.
        • Janavicius R.
        • Kleibl Z.
        • Kleiblova P.
        • Konstantopoulou I.
        • Kvist A.
        • Laduca H.
        • Lee A.S.
        • Lesueur F.
        • Maher E.R.
        • Mannermaa A.
        • Manoukian S.
        • McFarland R.
        • McKinnon W.
        • Meindl A.
        • Metcalfe K.
        • Taib N. Aishah Mohd
        • Moilanen J.
        • Nathanson K.L.
        • Neuhausen S.
        • Ng P. Sze
        • Nguyen-Dumont T.
        • Nielsen S.M.
        • Obermair F.
        • Offit K.
        • Olopade O.I.
        • Ottini L.
        • Penkert J.
        • PylkäsPylk K.
        • Radice P.
        • Ramus S.J.
        • Rudaitis V.
        • Side L.
        • Silva-Smith R.
        • Silvestri V.
        • Skytte A.-B.
        • Slavin T.
        • Soukupova J.
        • Tondini C.
        • Trainer A.H.
        • Unzeitig G.
        • Usha L.
        • van Overeem Hansen T.
        • Whitworth J.
        • Wood M.
        • Yip C. Har
        • Yoon S.-Y.
        • Yussuf A.
        • Zogopoulos G.
        • Goldgar D.
        • Hopper J.L.
        • Chenevix-Trench G.
        • Pharoah P.
        • George S.H.
        • Balmaña J.
        • Houdayer C.
        • James P.
        • El-Haffaf Z.
        • Ehrencrona H.
        • Janatova M.
        • Peterlongo P.
        • Nevanlinna H.
        • Schmutzler R.
        • Teo S.-H.
        • Robson M.
        • Pal T.
        • Couch F.
        • Weitzel J.N.
        • Elliott A.
        • Southey M.
        • Winqvist R.
        • Easton D.F.
        • Foulkes W.D.
        • Antoniou A.C.
        • Tischkowitz M.
        Downloaded from ascopubs.org by Institute of Oncology Ljubljana on, J Clin Oncol.
        38. 2020: 674-685https://doi.org/10.1200/JCO.19
        • Li B.T.
        • Makker V.
        • Buonocore D.J.
        • Offin M.D.
        • Olah Z.T.
        • Panora E.
        • Shen R.
        • Ho A.L.
        • Yaeger R.
        • Iyer G.
        • Ginsberg M.S.
        • Ulaner G.
        • Solit D.B.
        • Hyman D.M.
        • Rudin C.M.
        • Berger M.F.
        • Baselga J.
        • Scaltriti M.
        • Arcila M.E.
        • Kris M.G.
        A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.
        J. Clin. Oncol. 2018; 36: 2502https://doi.org/10.1200/jco.2018.36.15_suppl.2502
        • Jhaveri K.L.
        • Wang X.V.
        • Makker V.
        • Luoh S.-W.
        • Mitchell E.P.
        • Zwiebel J.A.
        • Sharon E.
        • Gray R.J.
        • Li S.
        • McShane L.M.
        • Rubinstein L.V.
        • Patton D.
        • Williams P.M.
        • Hamilton S.R.
        • Conley B.A.
        • Arteaga C.L.
        • Harris L.N.
        • O’Dwyer P.J.
        • Chen A.P.
        • Flaherty K.T.
        Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH Trial (EAY131) Sub-protocol Q.
        Ann. Oncol. 2019; https://doi.org/10.1093/annonc/mdz291
        • Banerji U.
        • van Herpen C.M.L.
        • Saura C.
        • Thistlethwaite F.
        • Lord S.
        • Moreno V.
        • Macpherson I.R.
        • Boni V.
        • Rolfo C.
        • de Vries E.G.E.
        • Rottey S.
        • Geenen J.
        • Eskens F.
        • Gil-Martin M.
        • Mommers E.C.
        • Koper N.P.
        • Aftimos P.
        Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
        Lancet Oncol. 2019; 20: 1124-1135https://doi.org/10.1016/S1470-2045(19)30328-6
        • El-Sahwi K.
        • Bellone S.
        • Cocco E.
        • Cargnelutti M.
        • Casagrande F.
        • Bellone M.
        • Abu-Khalaf M.
        • Buza N.
        • Tavassoli F.A.
        • Hui P.
        • Silasi D.A.
        • Azodi M.
        • Schwartz P.E.
        • Rutherford T.J.
        • Pecorelli S.
        • Santin A.D.
        In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
        Br. J. Cancer. 2010; 102: 134-143https://doi.org/10.1038/sj.bjc.6605448
        • English D.P.
        • Roque D.M.
        • Carrara L.
        • Lopez S.
        • Bellone S.
        • Cocco E.
        • Bortolomai I.
        • Schwartz P.E.
        • Rutherford T.
        • Santin A.D.
        HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
        Gynecol. Oncol. 2013; 131: 753-758https://doi.org/10.1016/j.ygyno.2013.08.033
        • Lopez S.
        • Schwab C.L.
        • Cocco E.
        • Bellone S.
        • Bonazzoli E.
        • English D.P.
        • Schwartz P.E.
        • Rutherford T.
        • Angioli R.
        • Santin A.D.
        Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
        Gynecol. Oncol. 2014; 135: 312-317https://doi.org/10.1016/j.ygyno.2014.08.024
        • Ray-Coquard I.
        • Favier L.
        • Weber B.
        • Roemer-Becuwe C.
        • Bougnoux P.
        • Fabbro M.
        • Floquet A.
        • Joly F.
        • Plantade A.
        • Paraiso D.
        • Pujade-Lauraine E.
        Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.
        Br. J. Cancer. 2013; 108https://doi.org/10.1038/bjc.2013.183
        • Slomovitz B.M.
        • Jiang Y.
        • Yates M.S.
        • Soliman P.T.
        • Johnston T.
        • Nowakowski M.
        • Levenback C.
        • Zhang Q.
        • Ring K.
        • Munsell M.F.
        • Gershenson D.M.
        • Lu K.H.
        • Coleman R.L.
        Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
        J. Clin. Oncol. 2015; 33: 930-936https://doi.org/10.1200/JCO.2014.58.3401
        • Colombo N.
        • McMeekin D.S.
        • Schwartz P.E.
        • Sessa C.
        • Gehrig P.A.
        • Holloway R.
        • Braly P.
        • Matei D.
        • Morosky A.
        • Dodion P.F.
        • Einstein M.H.
        • Haluska F.
        Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.
        Br. J. Cancer. 2013; 108: 1021-1026https://doi.org/10.1038/bjc.2013.59
        • Santin A.D.
        • Filiaci V.
        • Bellone S.
        • Ratner E.S.
        • Mathews C.A.
        • Cantuaria G.
        • Gunderson C.C.
        • Rutledge T.
        • Buttin B.M.
        • Lankes H.A.
        • Frumovitz M.
        • Khleif S.N.
        • Huh W.K.
        • Birrer M.J.
        Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: an NRG Oncology study (NRG-GY008).
        Gynecol. Oncol. Rep. 2020; 31https://doi.org/10.1016/j.gore.2019.100532
        • De Jonge M.M.
        • Auguste A.
        • Van Wijk L.M.
        • Schouten P.C.
        • Meijers M.
        • Ter Haar N.T.
        • Smit V.T.H.B.M.
        • Nout R.A.
        • Glaire M.A.
        • Church D.N.
        • Vrieling H.
        • Job B.
        • Boursin Y.
        • De Kroon C.D.
        • Rouleau E.
        • Leary A.
        • Vreeswijk M.P.
        • Bosse T.
        Frequent homologous recombination deficiency in high-grade endometrial carcinomas.
        Clin. Cancer Res. 2019; 25: 1087-1097https://doi.org/10.1158/1078-0432.CCR-18-1443
        • Liu J.F.
        • Tayob N.
        • Campos S.M.
        • Wright A.A.
        • Krasner C.
        • Schumer S.
        • Horowitz N.S.
        • Veneris J.T.
        • Xiong N.
        • West G.
        • Quinn R.
        • Matulonis U.A.
        • Konstantinopoulos P.A.
        A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma [abstract].
        in: Soc. Gynecol. Oncol. Annu. Meet. 2020